2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization

被引：15

作者：

Harris, Christopher M. ^{[1
]}

Ericsson, Anna M. ^{[1
]}

Argiriadi, Maria A. ^{[1
]}

Barberis, Claude ^{[1
]}

Borhani, David W. ^{[1
]}

Burchat, Andrew ^{[1
]}

Calderwood, David J. ^{[1
]}

Cunha, George A. ^{[1
]}

Dixon, Richard W. ^{[1
]}

Frank, Kristine E. ^{[1
]}

Johnson, Eric F. ^{[1
]}

Kamens, Joanne ^{[1
]}

Kwak, Silvia ^{[1
]}

Li, Biqin ^{[1
]}

Mullen, Kelly D. ^{[1
]}

Perron, Denise C. ^{[1
]}

Wang, Lu ^{[1
]}

Wishart, Neil ^{[1
]}

Wu, Xiaoyun ^{[1
]}

Zhang, Xiaolei ^{[1
]}

Zmetra, Tami R. ^{[1
]}

Talanian, Robert V. ^{[1
]}

机构：

[1] Abbott Labs, Worcester, MA 01605 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2010年 / 20卷 / 01期

关键词：

MAPKAP-K2; MK2; TNF alpha; Diaminopyrimidine;

D O I：

10.1016/j.bmcl.2009.10.103

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We describe structure-based optimization of a series of novel 2,4-diaminopyrimidine MK2 inhibitors. Co-crystal structures (see accompanying Letter) demonstrated a unique inhibitor binding mode. Resulting inhibitors had IC50 values as low as 19 nM and moderate selectivity against a kinase panel. Compounds 15, 31a, and 31b inhibit TNF alpha production in peripheral human monocytes. (c) 2009 Elsevier Ltd. All rights reserved.

引用

页码：334 / 337

页数：4

共 50 条

[41] IRREVERSIBLE ENZYME INHIBITORS .82. CANDIDATE ACTIVE-SITE-DIRECTED IRREVERSIBLE INHIBITORS OF DIHYDROFOLIC REDUCTASE 7 . DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE I
BAKER, BR
JACKSON, GDF
MEYER, RB
JOURNAL OF PHARMACEUTICAL SCIENCES, 1967, 56 (05) : 566 - &
[42] Structure-based design of β-lactamase inhibitors.: 2.: Synthesis and evaluation of bridged sulfactams and oxamazins
Hubschwerlen, C
Angehrn, P
Gubernator, K
Page, MGP
Specklin, JL
JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (21) : 3972 - 3975
[43] Exploring the ring potential of 2,4-diaminopyrimidine derivatives towards the identification of novel caspase-1 inhibitors in Alzheimer’s disease therapy
Ransford Oduro Kumi
Opeyemi S. Soremekun
Abdul Rashid Issahaku
Clement Agoni
Fisayo A. Olotu
Mahmoud E. S. Soliman
Journal of Molecular Modeling, 2020, 26
[44] Acyl Dipeptides as reversible caspase inhibitors. Part 2: Further optimization
Linton, SD
Karanewsky, DS
Ternansky, RJ
Chen, N
Guo, M
Jahangiri, KG
Kalish, VJ
Meduna, SP
Robinson, ED
Ullman, BR
Wu, JC
Pham, B
Kodandapani, L
Smidt, R
Diaz, JL
Fritz, LC
von Krosigk, U
Roggo, S
Schmitz, A
Tomaselli, KJ
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (20) : 2973 - 2975
[45] Exploring the ring potential of 2,4-diaminopyrimidine derivatives towards the identification of novel caspase-1 inhibitors in Alzheimer's disease therapy
Kumi, Ransford Oduro
Soremekun, Opeyemi S.
Issahaku, Abdul Rashid
Agoni, Clement
Olotu, Fisayo A.
Soliman, Mahmoud E. S.
JOURNAL OF MOLECULAR MODELING, 2020, 26 (04)
[46] Orally active thrombin inhibitors.: Part 2:: Optimization of the P2-moiety
Lange, UEW
Baucke, D
Hornberger, W
Mack, H
Seitz, W
Höffken, HW
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (10) : 2648 - 2653
[47] A novel 2,4-diaminopyrimidine derivative as selective inhibitor of protein kinase C theta prevents allograft rejection in a rat heart transplant model
Kunikawa, Shigeki
Tanaka, Akira
Takasuna, Yuji
Tasaki, Mamoru
Chida, Noboru
BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (20) : 5499 - 5509
[48] Structure-based optimization of olomoucine, a CDK1/2 inhibitor.
Furet, P
Imbach, P
Capraro, HG
Ruetz, S
Meyer, T
Zimmermann, J
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 216 : U267 - U267
[49] Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors
Bamborough, Paul
Chung, Chun-wa
Furze, Rebecca C.
Grandi, Paola
Michon, Anne-Marie
Sheppard, Robert J.
Barnett, Heather
Diallo, Hawa
Dixon, David P.
Douault, Clement
Jones, Emma J.
Karamshi, Bhumika
Mitchell, Darren J.
Prinjha, Rab K.
Rau, Christina
Watson, Robert J.
Wemer, Thilo
Demont, Emmanuel H.
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (15) : 6151 - 6178
[50] Discovery and Hit-to-Lead Optimization of Non-ATP Competitive MK2 (MAPKAPK2) Inhibitors
Huang, Xiaohua
Shipps, Gerald W., Jr.
Cheng, Cliff C.
Spacciapoli, Peter
Zhang, Xingmin
McCoy, Mark A.
Wyss, Daniel F.
Yang, Xianshu
Achab, Abdelghani
Soucy, Kyle
Montavon, Donna K.
Murphy, Denise M.
Whitehurst, Charles E.
ACS MEDICINAL CHEMISTRY LETTERS, 2011, 2 (08): : 632 - 637

← 1 2 3 4 5 →